Venous thromboembolism (VTE)—that is, deep venous thrombosis (DVT) and pulmonary embolism (PE)—are common complications after major hip or knee surgery. Without thromboprophylaxis, the incidence of DVT in patients undergoing major orthopaedic surgery is more than 50%, and fatal PE is reported to occur in 1–6% of these patients. These data are based on investigations in which predominantly osteoarthritis (OA) patients were studied. Only a few (small) studies were performed in rheumatoid arthritis (RA) patients: Abernethy reports an incidence of DVT of more than 70% and overall incidence of PE of approximately 2% in RA patients who have undergone a knee arthroplasty, and Kelly reports, in his review, an incidence of fatal PE of approximately 1% in RA patients undergoing total hip replacement and not receiving thromboprophylaxis (table 1). The risk of developing DVT seems to be similar for RA patients undergoing total hip replacement and those undergoing knee replacement surgery.

Data are conflicting regarding the risk for developing VTE for RA patients in comparison with OA patients undergoing major orthopaedic surgery. Similar incidences of VTE have been reported for OA patients undergoing major orthopaedic surgery, whereas one large retrospective study indicated a possibly lower rate of thromboembolic complications in RA patients (table 1). In this investigation, inhospital morbidity and mortality of 721 RA patients and 8859 OA patients, who underwent an elective hip replacement operation, were analysed retrospectively. The incidence of thromboembolic events was 0.3% in the RA group versus 1.2% in the OA group (p = 0.07). At first sight, these very low incidences of VTE are remarkable, but they are probably related to a very short observation period and underdiagnosing, by only observing clinical VTE. Hence, the incidence of VTE seems to be underestimated in this study.

Altogether, it remains unknown whether there is a difference in VTE risk between RA and OA patients and obviously, more reliable data should come from (prospective) investigations with adequate end point assessment.

### Development of venous thrombosis during/after (orthopaedic) surgery

Hypercoagulability, caused by tissue damage and intraoperative and postoperative stasis, is a common pathogenic factor for the development of DVT, in all surgical patients. Additional pathogenic factors play an important part in major orthopaedic procedures. The femoral vein is distorted and kinked during total hip replacement. This leads to stasis of blood and to vessel wall damage, which promotes fibrin formation. In addition, it leads to a local exhaustion of tissue plasminogen activator (t-PA), the activator of the fibrinolytic system. This results in an insufficient suppression of the local fibrin formation that occurs during the operation.

During total knee arthroplasty, tourniquets are usually applied to reduce blood loss and this results in stasis of blood and anoxia in the distal portion of the leg, which also leads to an exhaustion of endothelial t-PA stores and inadequate inhibition of fibrin formation.

Patients who have undergone major orthopaedic surgery develop swelling in the operated region, partly because of inflammatory reactions and partly because of wound haematomas, which may result in leg vein compression and stasis of blood.

The incidence of t-PA stores, in addition to local venous endothelial damage and blood stasis, leads to an increased perioperative fibrin formation and may explain the high incidences of VTE in major orthopaedic surgery.

The peak incidence of DVT is observed around the fifth postoperative day. After the first postoperative week a second activation of coagulation occurs, as demonstrated by an increase of thrombin-antithrombin III complexes and D-dimer, markers of coagulation activation, which may persist up to six weeks or longer. The pathophysiological mechanism for this activation is not known, but it might be partly attributable to a (relative) immobilisation of the patient after hospital discharge in addition to the discontinuation of pharmacological thromboprophylaxis.

### Need for thromboprophylaxis during hospitalisation

Obviously, thromboprophylaxis is mandatory in patients undergoing major orthopaedic surgery and presently, during the hospitalisation period, low molecular weight heparin (LMWH) is the most commonly applied thromboprophylactic agent in the majority of the orthopaedic surgery units in Europe. The evidence for the efficacy and safety of LMWH is derived from (large) trials in which predominantly OA patients were studied. However, although no conclusions for RA patients could be drawn in view of the very limited number of RA patients studied, LMWH is also commonly used in RA patients as thromboprophylaxis.

Numerous investigations and several meta-analyses have demonstrated the efficacy and safety of LMWH in the prevention of postoperative thromboembolic events after major orthopaedic surgery (table 2). Several studies have compared LMWH with unfractionated heparin in patients undergoing major orthopaedic surgery, indicating an overall risk reduction of approximately 25% for the

<table>
<thead>
<tr>
<th>Study</th>
<th>Patients (n)</th>
<th>Operation</th>
<th>Patients category</th>
<th>Deep vein thrombosis (%)</th>
<th>Pulmonary embolism (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Veneographically assessed DVT</td>
<td>—</td>
<td>THR</td>
<td>not reported</td>
<td>50</td>
<td>1–6</td>
</tr>
<tr>
<td>Kelly</td>
<td>—</td>
<td>THR</td>
<td>OA</td>
<td>50</td>
<td>1</td>
</tr>
<tr>
<td>Abernethy</td>
<td>55</td>
<td>THR</td>
<td>RA</td>
<td>70</td>
<td>2</td>
</tr>
<tr>
<td>Stringer</td>
<td>—</td>
<td>THR</td>
<td>RA</td>
<td>56</td>
<td>2</td>
</tr>
<tr>
<td>Clinically assessed DVT</td>
<td>8 859 721</td>
<td>THR THR</td>
<td>OA RA</td>
<td>1.2% 0.3%</td>
<td></td>
</tr>
</tbody>
</table>

development of DVT and an approximately 50% risk reduction for PE, when comparing LMWH with unfracti-

tionated heparin, without an increase of major bleeding complications.11 13

However, there is still a considerable rate of symptomless

DVT, approximately 15–20% at the end of the hospital

stay.12

Is post-discharge thromboprophylaxis needed?

Despite this high residual rate of approximately 15–20%

and laboratory evidence of continuing coagulation activa-

tion, there is no consensus whether or not prophylaxis

should be continued after hospital discharge in OA or RA

patients who have undergone major orthopaedic surgery.

Reduction of post-discharge VTE by anticoagulants should be carefully weighed against risk of bleeding and the

concomitant costs. To date, no conclusive evidence, particularly for RA patients, is available and presently, many orthopaedic surgeons in the Netherlands continue thromboprophylaxis after hospital discharge for six weeks up to three months, for which oral anticoagulants, mostly

acenocoumarol, are used. This practice is based on one

small scale investigation in which a total of 101 patients, 87

OA patients and 14 RA patients, undergoing elective total

hip replacement, were studied. All patients received oral

anticoagulants as thromboprophylaxis during the hospital

stay, which was stopped at the time of the hospital
discharge. This study indicated a high rate of post-
discharge non-fatal symptomatic PE, which was observed

in three of 55 patients (7%) with negative radionuclide

venography 10 days after the operation.14 The major draw-

back of this investigation is that the applied detection

method, radionuclide venography, is not an adequate

screening test for detecting (symptomless) DVT, which can

only be detected properly by contrast venography.15 Hence,

the PE observed in this investigation might have come from

patients with a false negative radionuclide venography and therefore, the true post-discharge incidence of PE might be

overestimated.

Recently, a much lower incidence of post-discharge PE

was reported.16 In this large open trial the occurrence of post-
discharge clinically overt VTE in patients not receiv-
ing prolonged prophylaxis was investigated. A total of

almost 2000 patients (predominantly OA), undergoing hip

or knee arthroplasty, were studied and clinically overt VTE

was observed in 40 patients (2%). DVT was detected in 25

patients, non-fatal PE in 14 patients and one patient

suffered from a fatal PE. To date, no data regarding the incidence of post-discharge VTE in RA patients have been published.

Thus far, the routine use as well as the duration of post-
discharge anticoagulation with oral anticoagulants has never been resolved properly for major orthopaedic surgery patients. Investigations in other patient categories (for example, treatment of VTE) indicate, per treated patient, a major bleeding risk (requiring hospitalisation) of 1–8% and a fatal bleeding rate of 0.5–4.8%.14 15 An important point of

consideration, is the additional bleeding risk if a non-

steroidal anti-inflammatory drug (NSAID) is used in combi-

nation with oral anticoagulants.16 For instance, the relative risk for a gastrointestinal bleeding or perforation is

more than six times increased when a NSAID is used in addition to oral anticoagulants.17 These bleeding risks also favour withholding prolonged thromboprophylaxis. Addition-

tal arguments are:

(1) the clinical significance of symptomless DVT is not

known, although it is generally accepted, that some will

lead to symptomatic DVT and PE,18 19 20 and others to the post-thrombotic syndrome;19 20

(2) immobilisation, an important risk factor for the devel-

opment of VTE during hospital stay,21 has only a lim-

ited significance at the time of the hospital discharge, as

most patients are then ambulant

(3) a thromboprophylactic effect has been suggested for

NSAIDs,19 20 and therefore, prolonged prophylaxis

would not be required for RA patients as most are

using NSAIDs.

Altogether, it seems that the balance between benefit and risk for prolonged (post-discharge) anticoagulation, par-

ticularly for RA patients, has not yet been elucidated.

Do aspirin and other NSAIDs have an effect on venous thromboembolism?

Aspirin irreversibly inhibits cyclooxygenase by acetylation whereas other NSAIDs produce a reversible inhibition by competing, with the substrate arachidonic acid, for the active site on the enzyme. The major mechanism for the well established (arterial) anti-thrombotic effect of aspirin is mediated through its ability to irreversibly block the syn-

thesis of platelet thromboxane A2.22

Classically the arterial thrombus is largely composed of

platelets and fibrin and therefore, arterial thrombi are

known as white thrombi. Venous thrombi have a much

richer content of erythrocytes and are therefore known as

red thrombi. Hence, it is conceivable that, from a pathophysiological point of view, aspirin (and other

NSAIDs), because of their inhibition of platelet aggrega-

tion, have a more pronounced (inhibitory) effect on the development of arterial thrombi compared with venous

thrombi.

For NSAIDs also a prophylactic effect on the develop-

ment of VTE has been hypothesised.

Table 2 Inhospital venous thromboembolism, with thromboprophylaxis, in major orthopaedic surgery patients

<table>
<thead>
<tr>
<th>Study</th>
<th>Patients (n)</th>
<th>Operation</th>
<th>Patients category</th>
<th>Thrombo prophylaxis</th>
<th>Deep vein thrombosis (%)</th>
<th>Pulmonary embolism (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leclerc et al</td>
<td>1141 842</td>
<td>THR TKR</td>
<td>not reported</td>
<td>LMWH</td>
<td>1.3 1.8</td>
<td>0.5 0.4</td>
</tr>
<tr>
<td>Nurmohamed et al</td>
<td>672</td>
<td>THR</td>
<td>OA (n=87); RA (n=14)</td>
<td>LMWH</td>
<td>14 4</td>
<td>2 0</td>
</tr>
<tr>
<td>Swirestra et al</td>
<td>101</td>
<td>THR</td>
<td>OA (n=87); RA (n=14)</td>
<td>OAC</td>
<td>23† 0</td>
<td>0 0</td>
</tr>
<tr>
<td>Howard et al</td>
<td>1599</td>
<td>TKR</td>
<td>not reported</td>
<td>LMWH</td>
<td>32 0.3</td>
<td>0.3 0.0</td>
</tr>
<tr>
<td>Cliniacally assessed DVT</td>
<td>436</td>
<td>TKR</td>
<td>OA (n=382); RA (n=54)</td>
<td>aspirin</td>
<td>42 39</td>
<td>not reported</td>
</tr>
</tbody>
</table>

*Meta-analysis. LMWH=low molecular weight heparin. OAC=oral anticoagulants. †Overall incidence. DVT=deep venous thrombosis. THR=total hip replacement. RAv=total knee replacement. OA=oral anticoagulation.
whereas this effect was not observed for the induction of venous thrombosis. The number of emboli generated from these thrombi as well as the duration of embolisation were, for both arterial and venous thrombi, significantly decreased by NSAIDs compared with control. This experiment suggests that NSAIDs have a more pronounced inhibitory effect on the development of arterial thrombosis on venous thrombus formation and a similar effect on arterial and venous emboli.

**Clinical Investigations**

A meta-analysis of earlier venous thromboprophylaxis trials among surgical and medical patients, in which antiplatelet agents (primarily aspirin) were investigated as thromboprophylactic agents, indicated some beneficial effect of aspirin against DVT in elective orthopaedic surgery. Thirteen elective orthopaedic surgery trials were considered for this analysis and encompassed a total of 863 patients. Antiplatelet therapy was administered to 427 patients, whereas there were 436 control patients. DVT was detected in 232 control patients (53.2%) and in 160 antiplatelet treated patients (37.5%, 49% odds reduction). Although the reduction seems substantial, these results must be interpreted cautiously as most studies that were included in this meta-analysis, suffered from methodological deficiencies, such as an open study design and inadequate end points. Hence, this meta-analysis cannot be considered conclusive regarding the effect of aspirin on the prevention of VTE. A thromboprophylactic effect on VTE of NSAIDs other than aspirin, has never been proved in recent clinical investigations. This is probably related to the fact that in most thromboprophylaxis trials NSAIDs were either stopped, or their use was strongly discouraged or patients using NSAIDs were excluded. Altogether, there seems no clinically relevant effect of aspirin (and other NSAIDs) in the prevention of venous thromboembolism, in contrast with the well established efficacy of aspirin in preventing arterial thrombosis.

NSAIDs are used by most RA patients and, to a lesser extent, by OA patients. They are stopped postoperatively in the majority of OA patients whereas they are continued, and still used after hospital discharge, in RA patients. Therefore, the balance of benefit—that is, reduction of post-discharge thromboembolism—and risk—that is, induction of bleeding complications—could be different for RA patients compared with OA patients.

**Post-discharge thromboprophylaxis**

Recently, four randomised double blind studies investigating extended prophylaxis with LMWH after hospital discharge were reported. The investigations had a comparable design involving post-discharge randomisation to either additional LMWH for a period of up to five weeks, or placebo. Almost 900 OA patients undergoing total hip replacement were investigated and large risk reductions of 40–60%, with residual DVT incidences of 4 up to 19%, during the post-hospitalisation period, were observed (table 3). There was no increased risk of bleeding complications or other adverse events in the LMWH groups. However, only a very limited number of RA patients were studied (for example, only 1 of 179 patients studied in the trial of Planes and coworkers, had RA) and therefore, these encouraging results cannot be extrapolated to RA patients.

In addition, a comparison with oral anticoagulants, the commonly applied drug for prolonged thromboprophylaxis in the Netherlands, is lacking and finally, the optimal duration of post-discharge thromboprophylaxis is not known.

Therefore, extended pharmacological prophylaxis of VTE in RA patients, undergoing major orthopaedic interventions, continues to be a serious matter of debate, which only can be solved by an appropriate trial.

**Conclusions**

VTE is an important postoperative complication of major orthopaedic surgery in OA and RA patients, albeit that, in RA patients, the risk for developing VTE might be lower in OA patients. LMWH effectively reduces the incidence of VTE during hospital stay in OA patients. LMWH is also commonly used as postoperative thromboprophylaxis in RA patients but this has never been validated.

The incidence of post-discharge VTE in OA patients seems to be substantial, and there is accumulating evidence that this can be safely lowered by prolonged administration of LMWH.

No data are available regarding the magnitude of post-discharge VTE in RA patients. The risk of RA patients might be different in comparison with OA patients in view of (a) an a priori possibly lower incidence of VTE during hospital stay and (b) post-discharge use of NSAIDs, which is accompanied by an increased bleeding risk if they are used in combination with anticoagulants. Hence, the balance of benefit and risk might be quite different for RA patients in comparison with OA patients.

Clearly there is a need for a randomised placebo controlled trial with LMWH and objective end point assessment (that is, venography) that investigates this topic. Only after the results of such an investigation become available, can definitive recommendations regarding extended thromboprophylaxis for RA patients undergoing major orthopaedic surgery be given—that is, whether it is warranted or dangerous.

M T Nurmohamed

Department of Rheumatology, Slotervaart Hospital and Jan van Breemen Institute, Amsterdam, the Netherlands

W F Lems

B A C Dijkmans

Department of Rheumatology, Slotervaart Hospital, Department of Rheumatology, Free University Hospital, and Jan van Breemen Institute, Amsterdam, the Netherlands

---
